提醒成功
微信/QQ登錄
搜索
首頁
| 產品規范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00048 |
| Application | Flow cytometry, animal model study |
| Aliases | ITGA4, CD49D, IA4, integrin subunit alpha 4 |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG4 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human Integrin alpha 4 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
Natalizumab Biosimilar uses the same protein sequences as the therapeutic antibody natalizumab. Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s). |
Natalizumab Biosimilar, Integrin alpha 4 Monoclonal Antibody B00048
產品中心
Product技術服務
service客戶留言
message